Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Amer Sports, Inc. in connection with its listing on the NYSE with credit facilities and issuance of bonds
Mandate

Vinge has advised Amer Sports, Inc. in connection with its listing on the NYSE with credit facilities and issuance of bonds

March 26, 2024

Vinge has advised Amer Sports, Inc. in connection with the listing of the company on the New York Stock Exchange with 105,000,000 shares at a value of USD 1.37 billion, whereby Vinge has assisted Amer Sports, Inc. and its subsidiaries with regulatory matters and the establishment of credit facilities of USD 500 million and EUR 700 million respectively and with the issuance of USD 800 million senior secured bonds where the Swedish subsidiaries have provided certain guarantees.

Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, Peak Performance and Atomic. Amer Sports has over 10,800 employees and operates in 41 countries.

 

Vinge's team consisted of Fredrik Wilkens, Henrik Schön, David Flodin, Linn Adelwald, Arvid Weimers and Jolinn Uhlin.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025